BrightGene Bio-Medical Technology Co., Ltd.

SHSE:688166 Stock Report

Market Cap: CN¥11.1b

BrightGene Bio-Medical Technology Future Growth

Future criteria checks 3/6

BrightGene Bio-Medical Technology is forecast to grow earnings and revenue by 21.8% and 16.4% per annum respectively. EPS is expected to grow by 21.9% per annum. Return on equity is forecast to be 10.5% in 3 years.

Key information

21.8%

Earnings growth rate

21.9%

EPS growth rate

Pharmaceuticals earnings growth18.4%
Revenue growth rate16.4%
Future return on equity10.5%
Analyst coverage

Low

Last updated15 Jul 2024

Recent future growth updates

No updates

Recent updates

Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding

Aug 01
Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding

BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

May 21
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 01
BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Earnings and Revenue Growth Forecasts

SHSE:688166 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,8903543034591
12/31/20251,5462851463881
12/31/20241,326227363081
3/31/20241,215196-48318N/A
12/31/20231,180202-209195N/A
9/30/20231,160234-185204N/A
6/30/20231,104237-161319N/A
3/31/20231,074250-176366N/A
12/31/20221,017240-415311N/A
9/30/20221,076265-533299N/A
6/30/20221,074249-665207N/A
3/31/20221,112256-821143N/A
12/31/20211,052244-734176N/A
9/30/20211,023225-765149N/A
6/30/2021961203-656109N/A
3/31/2021844184-439164N/A
12/31/2020785170-200155N/A
9/30/2020700169-50144N/A
6/30/2020596143-32117N/A
3/31/2020544129-3870N/A
12/31/2019503111-2861N/A
9/30/201946696-2041N/A
6/30/201944583-10052N/A
3/31/201941074-9143N/A
12/31/201840873-4864N/A
12/31/201731746N/A36N/A
12/31/201620117N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688166's forecast earnings growth (21.8% per year) is above the savings rate (2.9%).

Earnings vs Market: 688166's earnings (21.8% per year) are forecast to grow slower than the CN market (22.2% per year).

High Growth Earnings: 688166's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688166's revenue (16.4% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 688166's revenue (16.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 688166's Return on Equity is forecast to be low in 3 years time (10.5%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.